GeneDx Holdings Corp. (WGS) stock
WGSNasdaqServices-Health ServicesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$51.02−1.35 (-2.58%)
Close on Nov 16, 2026Market cap $1.52BP/E –Yield –
GeneDx ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
GeneDx's ebitda for the twelve months ending Jun 30, 2026 was -$81.47M, down 666.5% year over year. For fiscal 2025 it was -$3.48M. The highest annual figure on record is -$3.48M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.48M | – |
| FY2024 | Dec 31, 2024 | -$15.31M | – |
| FY2023 | Dec 31, 2023 | -$160.90M | – |
| FY2022 | Dec 31, 2022 | -$617.65M | – |
| FY2021 | Dec 31, 2021 | -$424.34M | – |
| FY2020 | Dec 31, 2020 | -$230.26M | – |
| FY2019 | Dec 31, 2019 | -$24.01M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$14.36M | -227.5% |
| Q1 FY2026 | Mar 31, 2026 | -$54.77M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.46M | -205.8% |
| Q3 FY2025 | Sep 30, 2025 | -$881.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $11.26M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.35M | – |
| Q4 FY2024 | Dec 31, 2024 | $10.83M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.36M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.87M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.92M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.07M | – |
| Q3 FY2023 | Sep 30, 2023 | -$37.80M | – |
| Q2 FY2023 | Jun 30, 2023 | -$44.80M | – |
| Q1 FY2023 | Mar 31, 2023 | -$55.23M | – |
| Q4 FY2022 | Dec 31, 2022 | -$294.31M | – |
| Q3 FY2022 | Sep 30, 2022 | -$83.82M | – |
| Q2 FY2022 | Jun 30, 2022 | -$156.02M | – |
| Q1 FY2022 | Mar 31, 2022 | -$83.50M | – |
| Q4 FY2021 | Dec 31, 2021 | -$109.99M | – |
| Q3 FY2021 | Sep 30, 2021 | -$82.77M | – |
| Q2 FY2021 | Jun 30, 2021 | -$39.83M | – |
| Q1 FY2021 | Mar 31, 2021 | -$191.76M | – |
| Q4 FY2020 | Dec 31, 2020 | -$121.46M | – |
| Q3 FY2020 | Sep 30, 2020 | -$52.95M | – |
See a number that looks wrong?